Agenus (FRA:AJ8) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AJ8 Agenus Inc FRA:AJ8
48 GF Score
Price €6.10
GF Value €3.22
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Agenus FFO?

FFO (Funds from operations) only applies to REITs.

FRA:AJ8
48GF Score
Agenus Inc FRA:AJ8
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agenus (FRA:AJ8) Overvalued in 2026?

Based on GuruFocus' analysis, Agenus stock appears to be overvalued. The current stock price of €6.10 is trading 89.4% above its estimated GF Value™ of €3.22. GuruFocus considers Agenus to be Significantly Overvalued.

Key valuation signals for FRA:AJ8:

  • FFO:
  • GF Value™: €3.22 vs. price of €6.10 (89.4% above fair value)
  • GF Score™: 48/100 with 12 warning signs

No single metric tells the full story. See the FRA:AJ8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agenus Business Description

Other Exchanges AGEN:USA
Address 3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
48GF Score

Get the complete analysis for FRA:AJ8

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.10
Price
€3.22
GF Value